218 completed, 143 unknown, 45 recruiting, 33 terminated. 110 Phase 4, 109 Phase 2, 93 Phase 1, 54 Not applicable, 51 Phase 3.
Follow Chronic Hepatitis B: new trials by email Literature Review of Chronic Hepatitis B trials Research Report on Chronic Hepatitis B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Targeting ANKRD11 Reverses HBV-Specific CD8+ T Cell Dysfunction and Tolerance Chronic Hepatitis B | Not yet recruiting | Beijing Municipal Administration of Hospitals | 40 | 2026-12-01 | 2026-08-28 | |
| A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) AHB-137, Placebo, TVAX-008 - Chronic Hepatitis B | Phase 1 / Phase 2 | Not yet recruiting | Ausper Biopharma Co., Ltd. | 105 | 2026-10-31 | 2026-10-19 |
| A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) AHB-137, TVAX-008, Placebo - Chronic Hepatitis B | Phase 1 / Phase 2 | Not yet recruiting | Grand Theravac Life Sciences (Hangzhou) Co., Ltd. | 105 | 2026-10-31 | 2026-10-27 |
| Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B ACT500 Tablets, ACT500 Placebo Tablets - Metabolic Dysfunction-associated Steatotic Liver Disease, Chronic Hepatitis b | Phase 1 | Not yet recruiting | Xiamen Amoytop Biotech Co., Ltd. | 24 | 2026-10-30 | 2026-09-14 |
| Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC) Hepatocellular Carcinoma, Liver Cirrhosis | Not yet recruiting | D'Or Institute for Research and Education | 300 | 2026-09-15 | 2026-08-14 | |
| Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response TQA3605 tablets Placebo, TQA3605 tablets, Entecavir dispersible tablets - Chronic Hepatitis B | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 930 | 2026-09-01 | 2026-10-02 |
| Sequential PD-1 Antibody and Pegylated Interferon Therapy for Nucleos(t)Ide Analogue-suppressed Chronic Hepatitis B Sintilimab, Pegylated Interferon-α 2b, Nucleos(t)ide Analogues - Chronic Hepatitis B | Not applicable | Not yet recruiting | Beijing 302 Hospital | 60 | 2026-09-01 | 2026-09-09 |
| A Study on the Consistency Evaluation of Digital PCR Technology for Quantitative Detection of HBV Nucleic Acid the results were classified according to concentration levels - Chronic Hepatitis b | Not yet recruiting | Beijing Municipal Administration of Hospitals | 200 | 2026-08-01 | 2026-07-07 | |
| Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B GST-HG141, GST-HG131, GST-HG141 Placebo - Chronic Hepatitis B | Phase 2 | Recruiting | Fujian Akeylink Biotechnology Co., Ltd. | 80 | 2026-07-10 | 2026-07-17 |
| A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function. AHB-137 injection - Chronic Hepatitis B | Phase 1 | Recruiting | Ausper Biopharma Co., Ltd. | 32 | 2026-07-09 | 2026-07-29 |
| Impact of Functional Cure of Chronic Hepatitis B on Patient-Reported Outcomes (PROs) Observation-based data collection via patient-reported questionnaires - Chronic Hepatitis B | Recruiting | Zhiliang Gao | 400 | 2026-07-01 | 2026-10-02 | |
| Phase IIIB Extension Clinical Trial of Efficacy and Safety of GST-HG141 (Nairevir) Combined With NAs in Chronic Hepatitis B GST-HG141 - Chronic Hepatitis b | Phase 3 | Not yet recruiting | Fujian Akeylink Biotechnology Co., Ltd. | 576 | 2026-06-26 | 2026-05-14 |
| A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B AHB-137, Placebo - Chronic Hepatitis B | Phase 2 | Recruiting | Ausper Biopharma Co., Ltd. | 320 | 2026-06-05 | 2026-07-29 |
| Adaptability of an Undetectable = Untransmissible Model for HBV Chronic Hepatitis b, Viremia | Recruiting | NYU Langone Health | 55 | 2026-05-01 | 2026-05-15 | |
| Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatitis B Patients Agent Intelligence education - Chronic Hepatitis B | Not applicable | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2000 | 2026-05-01 | 2026-04-09 |
| A Study on the Pursuit of Sustained Clearance of HBsAg in Chronic Hepatitis B(CHB) Patients With Previous Interferon Treatment Using Pegylated Interferon Alpha PEG IFNα-2b monotherapy or combination therapy with NAs, NAs monotherapy group - Chronic Hepatitis b | Not yet recruiting | xieqing | 10000 | 2026-04-30 | 2026-04-17 | |
| Assessment of Treatment Adherence and Associated Factors in Chronic HepB Patients Supported by HBVCare HBVCare Mobile App - Chronic Hepatitis B | Not applicable | Recruiting | Institute of Gastroenterology and Hepatology, Vietnam | 70 | 2026-04-15 | 2026-05-15 |
| A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Therapeutic hepatitis B vaccine, Commercial Hepatitis B vaccine - Chronic Hepatitis b | Phase 1 / Phase 2 | Not yet recruiting | Vaxine Pty Ltd | 40 | 2026-03-01 | 2025-09-22 |
| Residual Histological Disease Across Treatment Pathways in Chronic Hepatitis B Chronic Hepatitis B | Completed | Istanbul Medeniyet University | 1201 | 2026-01-20 | 2026-10-13 | |
| Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B Entecavir, Entecavir + Pegylated interferon α-2b - Hepatitis B Virus Infection, Children | Phase 4 | Not yet recruiting | Qing-Lei Zeng | 80 | 2026-01-11 | 2026-01-16 |
Showing 20 of 508. Sign in to see all of them.
Hepatitis B, Chronic (508) · Hepatitis B (84) · Liver Cirrhosis (21) · Carcinoma, Hepatocellular (12) · Fibrosis (12) · Hepatitis (12) · Hepatitis, Chronic (9) · Fatty Liver (8) · Non-alcoholic Fatty Liver Disease (8) · Bronchiolitis Obliterans Syndrome (6) · Hepatitis C, Chronic (6) · Hepatitis C (5) · Recurrence (4) · Acquired Immunodeficiency Syndrome (3) · HIV Infections (3)
Blood-Borne Infections (508) · Chronic Disease (508) · Communicable Diseases (508) · Digestive System Diseases (508) · Disease Attributes (508) · Hepadnaviridae Infections (508) · Hepatitis, Viral, Human (508) · Infections (508) · Pathologic Processes (508) · Pathological Conditions, Signs and Symptoms (508) · DNA Virus Infections (507) · Virus Diseases (507) · Liver Diseases (506) · Hepatitis, Chronic (499) · Hepatitis (496)
entecavir (80) · Tenofovir (73) · peginterferon alfa-2a (41) · tenofovir alafenamide (31) · Telbivudine (25) · adefovir dipivoxil (25) · Lamivudine (23) · adefovir (16) · nas (11) · peginterferon alfa-2b (10) · clevudine (8) · Nucleosides (7) · ((1-((2-amino-9H-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonic acid dipivoxyl (5) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (5) · hepatitis B hyperimmune globulin (4)
Gilead Sciences (30) · Beijing Ditan Hospital (20) · Third Affiliated Hospital, Sun Yat-Sen University (18) · Assembly Biosciences (17) · Bristol-Myers Squibb (12) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (11) · National Taiwan University Hospital (10) · Ausper Biopharma Co., Ltd. (9) · Chinese University of Hong Kong (9) · GlaxoSmithKline (9) · Novartis Pharmaceuticals (9) · Yonsei University (9) · Beijing 302 Hospital (8) · Bukwang Pharmaceutical (7) · Huashan Hospital (7)
China (228) · South Korea (91) · United States (67) · Taiwan (52) · New Zealand (50) · Hong Kong (47) · Canada (31) · Australia (28) · United Kingdom (25) · Germany (24) · France (22) · Singapore (22) · Thailand (21) · Italy (19) · Turkey (Türkiye) (17)
Hong Ren, MM (5) · Guiqiang Wang (4) · Liang Peng, Doctor (4) · Sang Hoon Ahn, MD, PhD (4) · Yao Xie, Doctor (4) · John Flaherty, PharmD (3) · Marc G Ghany, M.D. (3) · Pei-Jer Chen, M.D., Ph.D. (3) · Qing Xie (3)
PMID 19052126, PMID 28427875, PMID 25987775, PMID 28404091, PMID 28404092, PMID 35599306, PMID 16391218, PMID 16525137, PMID 18094378, PMID 19187608, PMID 20049753, PMID 20091678, PMID 20955704, PMID 21182232, PMID 22436845, PMID 23046671, PMID 23234725, PMID 23364953, PMID 23518903, PMID 23939953, PMID 24915612, PMID 25179493, PMID 25277773, PMID 25348661, PMID 25532501, PMID 25788199, PMID 27658343, PMID 28215615, PMID 29405329, PMID 30625297, PMID 30689258, PMID 30795958, PMID 31136052, PMID 32087795, PMID 35941076, PMID 37290591, PMID 42206582, PMID 10051494, PMID 12606735, PMID 14578866, PMID 14697813, PMID 14748059, PMID 15014185, PMID 15470215, PMID 15987917, PMID 16310901, PMID 16525138, PMID 16530509, PMID 16673294, PMID 16871563
2016 (3), 2004 (2), 2009 (2), 2014 (2), 2015 (2), 2019 (2), 2017 (1), 2023 (1), 2025 (1)